The best L-arginine supplements to support heart health
Over 80 million Americans have some form of cardiovascular disease. Arginine, also known as L-arginine, is a naturally occurring supplement that can help with many aspects of heart health. L-arginine can help people with clogged arteries or congestive heart failure by relaxing blood vessels and improving circulation.
L-arginine also has been linked to lowering blood pressure, helping with kidney function, and hastening wound healing. For a high-quality, time-released L-arginine supplement, the top choice is Thorne Research Perfusa-SR.
Who shouldn't take L-arginine supplements?
L-arginine affects circulation by relaxing blood vessels. Having a deficiency in L-arginine is rare, but a supplemental dose of the amino acid can be helpful for some conditions. However, anyone taking blood pressure medication, anticoagulants, heart medication, treatment for diabetes or erectile dysfunction pills, pregnant women and asthmatics should consult their doctor first before using L-arginine supplements.
What are the side effects of L-arginine supplements?
While clinical tests show that users can take L-arginine safely for up to three months, you should be aware of some minor side effects. Diarrhea, bloating, abdominal pain and gout have been reported by some users. Asthma patients should be aware that L-arginine could make breathing more difficult. Side effects from using L-arginine long-term have not been studied.
What do L-arginine supplements taste like?
In general, L-arginine tastes quite bitter due to its alkaline nature. You may want to consider mixing the powdered form of L-arginine with other liquids to mask the taste. Some L-arginine products are flavored.
Powder vs. capsule
Whether you choose powder or capsules, you will still be getting the same amount of L-arginine. There are some benefits to powder worth noting. It is slightly more cost-effective and requires just one dose daily. You can mix the powder form with other liquids and ingredients. The powder is also more quickly absorbed by the body, so the effects are felt more quickly. Pills are still a viable option for many because of their portability, the lack of bitter taste and they're less messy.
Forms of L-arginine
There are three different forms of L-arginine.
No preservatives
Look for L-arginine supplements without artificial preservatives or added sugar. Some L-arginine supplements include additional vitamins and folate for dietary support.
Basic unflavored L-arginine pills are available from $6-$10 per monthly supply, but they are not USDA-approved. Higher quality pills and powders are found in the $10-$20 range, while the premium L-arginine supplements that include additional nutritional support and flavor options will run $20 or more.
Are there other sources of L-arginine?
A. L-arginine occurs naturally in beef, poultry, fish, grain, seeds, nuts and dairy products. Consider increasing your intake of some of these foods if it meets your dietary needs.
Can I take L-arginine if I am taking lysine?
A. Take lysine and L-arginine several hours apart, as the two substances negate each other's effect if taken together.
Top L-arginine supplement
Thorne Research Perfusa-SR
What you need to know: This L-arginine supplement has a unique time-release that provides a consistent amino acid level throughout the day.
What you'll love: The manufacturer supplies supplements to the U.S. National Teams. Significant research studies confirm the product's positive effect on heart health. It has excellent absorption due to the sustained-release formula.
What you should consider: You will pay more for this product's unique benefits compared to other products similar to it.
Top L-arginine supplement for the money
NOW Foods Double Strength L-Arginine
What you need to know: Affordable and effective, this L-arginine supplement works as a nitric oxide precursor to dilate blood vessels.
What you'll love: The product is made in a facility that is certified to be kosher and free of GMOs. The manufacturer has been family-owned for over 50 years, employing high-tech technology and active in charitable causes.
What you should consider: Some reports of minor heartburn have been reported, and a small percentage of users did not notice any difference.
Worth checking out
Jarrow Formulas Arginine
What you need to know: This trusted brand of L-arginine supplement uses the highest grade ingredients in its production.
What you'll love: Formulated for exceptional absorption, this L-arginine supplement has no fillers or dyes and has been certified 99% pure. It supports heart and kidney health.
What you should consider: Single bottles are not available for purchase on all online retailers, where only two-bottle packs are sold.
BestReviews spends thousands of hours researching, analyzing and testing products to recommend the best picks for most consumers. BestReviews and its newspaper partners may earn a commission if you purchase a product through one of our links.
Distributed by Tribune Content Agency, LLC.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Talkiatry Chief Medical Officer and co-founder Dr. Georgia Gaveras, DO named to Modern Healthcare's 50 Most Influential Clinical Executives Class of 2025
NEW YORK, June 9, 2025 /PRNewswire/ -- Talkiatry, a leading provider of high-quality, in-network psychiatry and therapy services, is proud to announce that co-founder and Chief Medical Officer Dr. Georgia Gaveras, DO has been recognized by Modern Healthcare as one of the 50 Most Influential Clinical Executives for 2025. Detailed profiles of all the honorees are featured in the June 9, 2025 issue of Modern Healthcare's magazine and online at This program honors licensed clinicians in executive roles who are recognized by the senior editors of Modern Healthcare and selected for their exceptional achievements in driving innovation, improving outcomes, serving their communities, and demonstrating exemplary leadership both within and beyond their organizations. "Becoming a clinician doesn't automatically prepare one for a leadership role, helping to guide an organization or an industry. The 50 clinicians chosen this year as the most influential, some newcomers and some we have recognized previously, are having an oversized impact," said Mary Ellen Podmolik, editor-in-chief of Modern Healthcare. "Their work is benefiting their own teams in terms of clinical advancements and financial results and is leading to better patient outcomes." With more than 600 licensed psychiatrists and 150+ therapists treating children, adults, and seniors for conditions including ADHD, anxiety, bipolar disorder, depression, OCD, and PTSD, Talkiatry has expanded to 47 states and reaches over 70% of commercially insured Americans through partnerships with more than 60 insurance providers, including Blue Cross Blue Shield, Aetna, United Healthcare, Cigna, and Humana. As access has increased, Talkiatry's dedication to high-quality care continues to lead to positive patient outcomes. In peer-reviewed clinical findings, two out of three patients saw their anxiety symptoms drop below clinically significant levels, and a similar portion experienced the same improvement with depression. Notably, one out of three patients achieved full remission in under 15-weeks. Among those who did not reach these thresholds, the vast majority still reported measurable improvement. Talkiatry is a physician-led practice where quality care comes first. Clinicians have the autonomy to make the best decisions for their patients, supported by structured clinical leadership, peer collaboration, and continuous education. To deliver these outcomes, Talkiatry has built an environment that prioritizes clinician support and sustainability. All clinicians receive structured onboarding, access to ongoing clinical education, and support from dedicated teams that handle scheduling, billing, and credentialing. Talkiatry is a community of like-minded, mission-driven peers. Through clinical chats, mentorship, grand rounds, and peer case consultations, the organization fosters connection, knowledge sharing, and a sense of belonging. "This recognition is a testament to the vital work the Talkiatry team is doing to expand access to high quality mental health care, regardless of a patient's geography or circumstance. Being named one of Modern Healthcare's 50 Most Influential Clinical Executives reinforces the importance of our mission, and I am incredibly grateful to be part of a movement that is transforming the way mental health care is delivered in this country." - Dr. Georgia Gaveras, Co-Founder & Chief Medical Officer, Talkiatry. For information or questions about the 50 Most Influential Clinical Executives program, please contact: MH Awards mhawards@ About Modern HealthcareModern Healthcare is the most trusted business news and information brand in the healthcare industry. Modern Healthcare empowers healthcare leaders and influencers to make timely and informed business decisions. To learn more or subscribe, go to About TalkiatryTalkiatry is a national mental health practice that provides in-network psychiatry and therapy. Co-founded by Robert Krayn and Georgia Gaveras, DO, Talkiatry is solving the core challenges patients and clinicians face in accessing and providing high-quality mental healthcare. With over 2 million patient visits delivered by a growing team of 600+ full-time psychiatrists and 150+ full-time therapists, Talkiatry is the largest dedicated psychiatry practice in the U.S. Our technology platform removes administrative burdens so clinicians can focus solely on patient care, resulting in strong clinical outcomes and significantly lower burnout. At Talkiatry, we're reimagining psychiatric care to be accessible, human, and responsible. Learn more at and follow us on LinkedIn, Facebook, and Instagram. Media Contactpress@ View original content to download multimedia: SOURCE Talkiatry Sign in to access your portfolio
2 hours ago
NIH scientists publish declaration criticizing Trump's deep cuts in public health research
WASHINGTON -- In his confirmation hearings to lead the National Institutes of Health, Jay Bhattacharya pledged his openness to views that might conflict with his own. 'Dissent," he said, 'is the very essence of science.' That commitment is being put to the test. On Monday, scores of scientists at the agency sent their Trump-appointed leader a letter titled the Bethesda Declaration, a frontal challenge to 'policies that undermine the NIH mission, waste public resources, and harm the health of Americans and people across the globe.' It says: "We dissent." In a capital where insiders often insist on anonymity to say such things publicly, more than 90 NIH researchers, program directors, branch chiefs and scientific review officers put their signatures on the letter — and their careers on the line. They went public in the face of a 'culture of fear and suppression' they say President Donald Trump's administration has spread through the federal civil service. 'We are compelled to speak up when our leadership prioritizes political momentum over human safety and faithful stewardship of public resources,' the declaration says. Named for the agency's headquarters location in Maryland, the Bethesda Declaration details upheaval in the world's premier public health research institution over the course of mere months. It addresses the abrupt termination of 2,100 research grants valued at more than $12 billion and some of the human costs that have resulted, such as cutting off medication regimens to participants in clinical trials or leaving them with unmonitored device implants. In one case, an NIH-supported study of multi-drug-resistant tuberculosis in Haiti had to be stopped, ceasing antibiotic treatment mid-course for patients. In a number of cases, trials that were mostly completed were rendered useless without the money to finish and analyze the work, the letter says. 'Ending a $5 million research study when it is 80% complete does not save $1 million,' it says, 'it wastes $4 million.' The four-page letter, addressed to Bhattacharya but also sent to Health Secretary Robert F. Kennedy Jr. and members of Congress who oversee the NIH, was endorsed by 250 anonymous employees of the agency besides the 92 who signed. Jenna Norton, who oversees health disparity research at the agency's National Institute of Diabetes and Digestive and Kidney Diseases, recently appeared at a forum by Sen. Angela Alsobrooks, D-Md., to talk about what's happening at the NIH. At the event, she masked to conceal her identity. Now the mask is off. She was a lead organizer of the declaration. 'I want people to know how bad things are at NIH," Norton told The Associated Press. The signers said they modeled their indictment after Bhattacharya's own Great Barrington Declaration of October 2020, when he was a professor at Stanford University Medical School. His declaration drew together likeminded infectious disease epidemiologists and public health scientists who dissented from what they saw as excessive COVID-19 lockdown policies and felt ostracized by the larger public health community that pushed those policies, including the NIH. 'He is proud of his statement, and we are proud of ours," said Sarah Kobrin, a branch chief at the NIH's National Cancer Institute who signed the Bethesda Declaration. As chief of the Health Systems and Interventions Research Branch, Kobrin provides scientific oversight of researchers across the country who've been funded by the cancer institute or want to be. But sudden cuts in personnel and money have shifted her work from improving cancer care research to what she sees as minimizing its destruction. "So much of it is gone — my work,' she said. The 21-year NIH veteran said she signed because 'I don't want to be a collaborator' in the political manipulation of biomedical science. Ian Morgan, a postdoctoral fellow with the National Institute of General Medical Sciences, also signed the declaration. 'We have a saying in basic science,' he said. 'You go and become a physician if you want to treat thousands of patients. You go and become a researcher if you want to save billions of patients. 'We are doing the research that is going to go and create the cures of the future,' he added. But that won't happen, he said, if Trump's Republican administration prevails with its searing cuts to grants. The NIH employees interviewed by the AP emphasized they were speaking for themselves and not for their institutes or the NIH. Employees from all 27 NIH institutes and centers gave their support to the declaration. Most who signed are intimately involved with evaluating and overseeing extramural research grants. The letter asserts that 'NIH trials are being halted without regard to participant safety' and that the agency is shirking commitments to trial participants who 'braved personal risk to give the incredible gift of biological samples, understanding that their generosity would fuel scientific discovery and improve health.' The Trump administration has gone at public health research on several fronts, both directly, as part of its broad effort to root out diversity, equity and inclusion values throughout the bureaucracy, and as part of its drive to starve some universities of federal money. This has forced 'indiscriminate grant terminations, payment freezes for ongoing research, and blanket holds on awards regardless of the quality, progress, or impact of the science,' the declaration says. Some NIH employees have previously come forward in televised protests to air grievances, and many walked out of Bhattacharya's town hall with staff. The declaration is the first cohesive effort to register agency-wide dismay with the NIH's direction. A Signal group became the place for participants to sort through NIH chatter on Reddit, discern rumor from reality and offer mutual support. The declaration took shape in that group and as word spread neighbor to neighbor in NIH offices. The dissenters remind Bhattacharya in their letter of his oft-stated ethic that academic freedom must be a lynchpin in science. With that in place, he said in a statement in April, 'NIH scientists can be certain they are afforded the ability to engage in open, academic discourse as part of their official duties and in their personal capacities without risk of official interference, professional disadvantage or workplace retaliation." Now it will be seen whether that's enough to protect those NIH employees challenging the Trump administration and him. 'There's a book I read to my kids, and it talks about how you can't be brave if you're not scared,' said Norton, who has three young children. "I am so scared about doing this, but I am trying to be brave for my kids because it's only going to get harder to speak up. 'Maybe I'm putting my kids at risk by doing this," she added. "And I'm doing it anyway because I couldn't live with myself otherwise.'
Yahoo
2 hours ago
- Yahoo
Journey Medical Corporation Announces Emrosi™ Featured on 'The Balancing Act' Airing on Lifetime TV
National TV Segment Highlights FDA-Approved Treatment for Rosacea Segment premiered on Monday, June 9 and will be rebroadcast on Thursday, June 19, at 7:30 a.m. PT/ ET SCOTTSDALE, Ariz., June 09, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) ('Journey Medical' or 'the Company', 'we', or 'our'), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ('FDA') approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that a new segment of 'The Balancing Act®' airing on Lifetime TV and sponsored by the Company featured Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules), its FDA-approved treatment for inflammatory lesions of rosacea in adults. The segment premiered nationwide on Monday, June 9, at 7:30 a.m. PT / ET and provided expert insights on lifestyle considerations and treatment options for managing rosacea. 'We're proud to see Emrosi featured on 'The Balancing Act,' bringing national visibility to what we believe is a potential paradigm shift in the treatment of rosacea,' said Claude Maraoui, Co-Founder, President, and Chief Executive Officer of Journey Medical. 'This segment is an important opportunity to educate patients, caregivers and healthcare providers about Emrosi's unique formulation and benefits, as well as our broader commitment to advancing dermatologic care through innovative, patient-focused solutions.' The feature included insights from Pura Dermatology's Saurabh Lodha, MD, FAAD, who discussed Emrosi's unique formulation and its significance in the treatment landscape for rosacea. Approved by the U.S. Food and Drug Administration (FDA) in November 2024, Emrosi is the lowest-dose oral minocycline available, offering patients an effective treatment option with a favorable safety profile. It is available by prescription at specialty pharmacy chains. In addition to the June 9 premiere, the segment will be rebroadcast on Thursday, June 19, at 7:30 a.m. PT/ ET. It can also be viewed on the show's website, About RosaceaRosacea is a chronic, relapsing, inflammatory skin condition that most commonly presents with symptoms such as deep facial redness, acne-like inflammatory lesions (papules and pustules) and spider veins (telangiectasia). According to The National Rosacea Society, it is estimated that rosacea affects over 16 million Americans and as many as 415 million people worldwide. Rosacea is most frequently seen in adults between 30 and 50 years of age. Surveys conducted by The National Rosacea Society report that more than 90 percent of rosacea patients said their condition had lowered their self-confidence and self-esteem, and 41 percent stated that it had caused them to avoid public contact or cancel social engagements. Among rosacea patients with severe symptoms, 88 percent said the disorder had adversely affected their professional interactions, and 51 percent said they had missed work because of their condition. Important Safety InformationIndication: EMROSI™ is indicated for the treatment of inflammatory lesions (papules and pustules) of rosacea in adults. Adverse Events: The most common adverse reaction reported by ≥1% of subjects treated with EMROSI and more frequently than in subjects receiving placebo was dyspepsia. Contraindications: EMROSI should not be taken by patients who have a history of hypersensitivity to any of the tetracyclines. Warnings/Precautions: Cases of anaphylaxis, serious skin reactions (e.g., Stevens-Johnson syndrome), erythema multiforme, and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome have been reported postmarketing with minocycline use in patients with acne. If DRESS syndrome is recognized, discontinue EMROSI immediately. Use during the second and third trimesters of pregnancy, infancy and childhood up to the age of 8 years may cause permanent discoloration of the teeth and reversible inhibition of bone growth. Discontinue EMROSI use if Antibiotic-Associated Colitis occurs. Discontinue EMROSI if liver injury is suspected. Patients experiencing light-headedness, dizziness or vertigo should be cautioned about driving vehicles or operating heavy machinery. Clinical manifestations include headache, blurred vision, diplopia, and vision loss. Discontinue EMROSI immediately if symptoms occur. Symptoms may be manifested by fever, rash, arthralgia, and malaise. Discontinue EMROSI immediately if symptoms occur. Patients should minimize or avoid exposure to natural or artificial sunlight while using EMROSI. Tetracycline-class antibiotics are known to cause hyperpigmentation. EMROSI may induce hyperpigmentation in many organs, including nails, bone, skin, eyes, thyroid, visceral tissue, oral cavity, sclerae and heart valves. Because of the potential for drug-resistant bacteria to develop during the use of EMROSI, use EMROSI only as indicated. If superinfection occurs, discontinue EMROSI and institute appropriate therapy. Perform periodic laboratory evaluations of organ systems, including hematopoietic, renal and hepatic studies. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088 For full prescribing information, please visit About The Balancing ActThe Balancing Act® is a morning show created and produced by BrandStar that offers sensible solutions and essential information in a fun, entertaining format; providing resources to help people do life better. The Balancing Act features everything from delicious recipes, style makeovers and dream getaways to parenting tips and the latest news in health and wealth. Tune in to The Balancing Act weekdays at 7:30 a.m. (ET/PT) on Lifetime® and find all previously aired episodes on About Journey Medical CorporationJourney Medical Corporation (Nasdaq: DERM) ('Journey Medical') is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets eight FDA approved prescription drugs that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology's most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical's common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission ('SEC'). For additional information about Journey Medical, visit Forward-Looking StatementsThis press release may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words 'the Company', 'we', 'us' and 'our' may refer to Journey Medical. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. The words 'anticipate,' 'believe,' 'estimate,' 'may,' 'expect,' 'will,' 'could,' 'project,' 'intend,' 'potential' and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: the fact that our products and product candidates are subject to time and cost intensive regulation and clinical testing and as a result, may never be successfully developed or commercialized; a substantial portion of our sales derive from products that may become subject to third-party generic competition, the introduction of new competitor products, or an increase in market share of existing competitor products, any of which could have a significant adverse impact on our operating income; we operate in a heavily regulated industry, and we cannot predict the impact that any future legislation or administrative or executive action may have on our operations; our revenue is dependent mainly upon sales of our dermatology products and any setback relating to the sale of such products could impair our operating results; competition could limit our products' commercial opportunity and profitability, including competition from manufacturers of generic versions of our products; the risk that our products do not achieve broad market acceptance, including by government and third-party payors; our reliance third parties for several aspects of our operations; our dependence on our ability to identify, develop, and acquire or in-license products and integrate them into our operations, at which we may be unsuccessful; the dependence of the success of our business, including our ability to finance our company and generate additional revenue, on the successful commercialization of our recently approved product, EmrosiTM, and any future product candidates that we may develop, in-license or acquire; clinical drug development is very expensive, time consuming, and uncertain and our clinical trials may fail to adequately demonstrate the safety and efficacy of our current or any future product candidates; our competitors could develop and commercialize products similar or identical to ours; risks related to the protection of our intellectual property and our potential inability to maintain sufficient patent protection for our technology and products; our business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in our or our third parties' cybersecurity; the substantial doubt about our ability to continue as a going concern; the effects of major public health issues, epidemics or pandemics on our product revenues and any future clinical trials; our potential need to raise additional capital; Fortress controls a voting majority of our common stock, which could be detrimental to our other shareholders; as well as other risks described in Part I, Item 1A, 'Risk Factors,' in our Annual Report on Form 10-K for the year ended December 31, 2024, subsequent Reports on Form 10-Q, and our other filings we make with the SEC. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Company Contact:Jaclyn Jaffe (781) 652-4500ir@ Media Relations Contact:Tony Plohoros6 Degrees(908) 591-2839tplohoros@ in to access your portfolio
